Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer von FUKUOKA, Masahiro, YANO, Seiji, EEK, Richard, HORAI, Takeshi, NODA, Kazumasa, TAKATA, Ichiro, SMIT, Egbert, AVERBUCH, Steven, MACLEOD, Angela, FEYEREISLOVA, Andrea, DONG, Rui-Ping, BASELGA, José, GIACCONE, Giuseppe, TAMURA, Tomohide, NAKAGAWA, Kazuhiko, DOUILLARD, Jean-Yves, NISHIWAKI, Yutaka, VANSTEENKISTE, Johan, KUDOH, Shinzoh, RISCHIN, Danny

Volltext

A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145 von Kovacs, Michael J., Reece, Donna E., Marcellus, Deborah, Meyer, Ralph M., Mathews, Sarah, Dong, Rui-Ping, Eisenhauer, Elizabeth

Volltext

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer von Fukuoka, Masahiro, Yano, Seiji, Giaccone, Giuseppe, Tamura, Tomohide, Nakagawa, Kazuhiko, Douillard, Jean-Yves, Nishiwaki, Yutaka, Vansteenkiste, Johan, Kudoh, Shinzoh, Rischin, Danny, Eek, Richard, Horai, Takeshi, Noda, Kazumasa, Takata, Ichiro, Smit, Egbert, Averbuch, Steven, Macleod, Angela, Feyereislova, Andrea, Dong, Rui-Ping, Baselga, José

Volltext

Application of random quality control based on time -series model in ELISA detection of blood donors in Nanjing von Han, Wenping, Bao, Jingjing, Hu, Polu, Liu, Yang, Pang, Rongrong, Dong, Rui-ping, Zhang, Libo, Ma, Chengping

Volltext

Functional Interaction of DFF35 and DFF45 with Caspase-activated DNA Fragmentation Nuclease DFF40 von Gu, Jijie, Dong, Rui-Ping, Zhang, Chonghui, McLaughlin, Daniel F., Wu, Mei X., Schlossman, Stuart F.

Volltext

HLA-A and DPB1 loci confer susceptibility to Grave's disease von Dong, Rui-Ping, Kimura, Akinori, Okubo, Ryoko, Shinagawa, Hirotoshi, Tamai, Hajime, Nishimura, Yasuharu, Sasazuki, Takehiko

Volltext

Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response von Dong, RP, Kameoka, J, Hegen, M, Tanaka, T, Xu, Y, Schlossman, SF, Morimoto, C

Volltext

Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation von Dong, RP, Tachibana, K, Hegen, M, Munakata, Y, Cho, D, Schlossman, SF, Morimoto, C

Volltext

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer (Reprinted from vol 21, pg 2237-2246, 2003) von Fukuoka, Masahiro, Yano, Seiji, Giaccone, Giuseppe, Tamura, Tomohide, Nakagawa, Kazuhiko, Douillard, Jean-Yves, Nishiwaki, Yutaka, Vansteenkiste, Johan, Kudoh, Shinzoh, Rischin, Danny, Eek, Richard, Horai, Takeshi, Noda, Kazumasa, Takata, Ichiro, Smit, Egbert, Averbuch, Steven, Macleod, Angela, Feyereislova, Andrea, Dong, Rui-Ping, Baselga, Jose

Volltext

Sequence analysis of three novel DRw14-DRB1 alleles von RUI-PING DONG, KIMURA, A, SASAZUKI, T

Volltext

Sequencing and population analysis of four novel HLA-DPA1 alleles von Harada, Haruhito, Kimura, Akinori, Dong, Rui-Ping, Xu, Xing Pei, Bhatia, Kuldeep, Sasazuki, Takehiko

Volltext

HLA-A and -DRB4 genes in controlling the susceptibility to Hashimoto's thyroiditis von Wan, Xiao-Lin, Kimura, Akinori, Dong, Rui-Ping, Honda, Koji, Tamai, Hajime, Sasazuki, Takehiko

Volltext

Characterization of T cell epitopes restricted by HLA-DP9 in streptococcal M12 protein von Dong, RP, Kamikawaji, N, Toida, N, Fujita, Y, Kimura, A, Sasazuki, T

Volltext

EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy von YANO, Seiichi, YAMAGUCHI, Motonori, DONG, Rui-Ping

Volltext

HLA-Linked susceptibility and resistance to Takayasu Arteritis von Dong, Rui-Ping, Kimura, Akinori, Numano, Fujio, Nishimura, Yasuharu, Sasazuki, Takehiko

Volltext

Different regulatory effects of pentoxifylline on human T cell activation pathways von DONG, R.-P, UMEZAWA, Y, IKUSHIMA, H, MUNAKATA, Y, SCHLOSSMAN, S. F, MORIMOTO, C

Volltext

Immunogenetic analysis of silicosis in Japan von HONDA, K, KIMURA, A, RUI-PING DONG, TAMAI, H, NAGATO, H, NISHIMURA, Y, SASAZUKI, T

Volltext

A Novel Anti-EGFR Monoclonal Antibody, Cetuximab (Erbitux®) von Goto, Arata, Dong, RuiPing

Volltext

EGFR tyrosine kinase inhibitor “gefitinib (Iressa®)” for cancer therapy von YANO, Seiichi, YAMAGUCHI, Motonori, DONG, Rui-Ping

Volltext

A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relap... von Kovacs, Michael J., Reece, Donna E., Marcellus, Deborah, Meyer, Ralph M., Matthews, Sarah, Dong, Rui-Ping, Eisenhauer, Elizabeth

Volltext